Long-term oxygen therapy in patients with pulmonary artery hypertension

被引:0
|
作者
Subba, Sristina [1 ]
Johnshon, Saumy [3 ]
Devasia, Tom [2 ]
机构
[1] SOAHS, Dept Resp Therapy, Manipal, Karnataka, India
[2] KMC, Dept Cardiol, Manipal, Karnataka, India
[3] Inaya Med Coll, Dept Resp Therapy Sci, Riyadh, Saudi Arabia
关键词
Hypoxemia respiratory care; long-term oxygen therapy; pulmonary arterial hypertension; HYPOXIC COR-PULMONALE; SURVIVAL;
D O I
10.4103/ijrc.ijrc_17_18
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Introduction: Dyspnea associated with pulmonary arterial hypertension (PAH) requires supplemental oxygen to maintain oxygen saturation. Many researches related to oxygen therapy in chronic obstructive pulmonary disease and cor pulmonale are available, but the effect of long-term oxygen therapy (LTOT) has not been explored in PAH patients. Aim: This study aimed to determine the effect of LTOT in patients diagnosed with PAH. Methodology: All adult patients with PAH, primary or secondary to respiratory disease who require LTOT, were included in the study. The following parameters were collected: age, gender, severity of PAH based on echocardiogram, body mass index, comorbidities, type of oxygen therapy device, amount and duration of oxygen usage, mortality, frequency of readmission, oxygenation, and vital sign parameters. Results: This was a retrospective study which included 332 participants diagnosed to have PAH after detailed echocardiogram assessment. Out of these, 32 participants were prescribed LTOT at the time of discharge. At the time of discharge, there was a significant improvement in all the vital signs and oxygenation variables. The increase in oxygenation, hemoglobin, and reduced respiratory rate after LTOT was statistically significant (P < 0.001). During follow-up after 1 year, 26 (81.3%) participants survived, 3 participants (9.4%) expired, and 3 participants (9.4%) were lost to follow-up. Conclusion: The use of oxygen therapy is beneficial in patients with PAH in terms of improvement in oxygenation and reduction in hospital readmission. Survival at 1 year is 81% in patients using LTOT.
引用
收藏
页码:31 / 35
页数:5
相关论文
共 50 条
  • [41] NIFEDIPINE THERAPY FOR PULMONARY-HYPERTENSION - ACUTE AND LONG-TERM EFFECTS
    HOHNLOSER, S
    BONZEL, T
    WOLLSCHLAGER, H
    ZEIHER, A
    LOLLGEN, H
    JUST, H
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1984, 3 (02) : 578 - 578
  • [42] Long-Term Ambrisentan Therapy for Pulmonary Arterial Hypertension: Comparison by Etiology
    Pulido, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [43] Long-term continuous subcutaneous treprostinil therapy for pulmonary arterial hypertension
    Skoro-Sajer, N
    Harja, E
    Bonderman, D
    Rezaie-Majd, S
    Machherndl, S
    Kneussl, M
    Lang, MI
    EUROPEAN HEART JOURNAL, 2003, 24 : 483 - 483
  • [44] A case of long-term sildenafil therapy in a young dog with pulmonary hypertension
    Toyoshima, Yumiko
    Kanemoto, Isamu
    Arai, Satoshi
    Toyoshima, Hiroaki
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2007, 69 (10): : 1073 - 1075
  • [45] Children with pulmonary arterial hypertension and prostanoid therapy: Long-term hemodynamics
    Siehr, Stephanie L.
    Ivy, D. Dunbar
    Miller-Reed, Kathleen
    Ogawa, Michelle
    Rosenthal, David N.
    Feinstein, Jeffrey A.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2013, 32 (05): : 546 - 552
  • [46] Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
    Calcaianu, George
    Chaouat, Ari
    Canuet, Matthieu
    Kessler, Romain
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [47] Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension
    Lang, Irene
    Gomez-Sanchez, Miguel
    Kneussl, Meinhard
    Naeije, Robert
    Escribano, Pilar
    Skoro-Sajer, Nika
    Vachiery, Jean-Luc
    CHEST, 2006, 129 (06) : 1636 - 1643
  • [48] LONG-TERM OUTCOMES OF EPOPROSTENOL THERAPY IN SARCOID ASSOCIATED PULMONARY HYPERTENSION
    Abston, Erie
    Moll, Matthew
    Hon, Stephanie
    Govender, Praveen
    Berman, Jeffrey
    Farber, Harrison
    SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2020, 37 (02) : 184 - 191
  • [49] Long-Term Ambrisentan Therapy in Patients with Pulmonary Arterial Hypertension: An Analysis by WHO Functional Class
    Torres, F.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [50] Long-term survival in idiopathic pulmonary arterial hypertension associated with massive pulmonary artery dilation
    Petrovic, Vanja
    Ryerson, Christopher J.
    Levy, Robert D.
    CANADIAN RESPIRATORY JOURNAL, 2011, 18 (03) : E50 - E51